Liquidia Corporation filed a current report on September 3, 2026, disclosing that the U.S. Food and Drug Administration has granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis.

Key Highlights

  • FDA Fast Track Designation: The U.S. Food and Drug Administration granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder.
  • Target Indication: The designation covers treatment of Raynaud's phenomenon associated with systemic sclerosis.
  • Product: YUTREPIA is an inhalation powder formulation of treprostinil, a compound Liquidia has developed and commercialized.
  • Report Date: The event and the press release announcing it both occurred on September 3, 2026.
  • Signatory: The filing was signed by Michael Kaseta, Chief Financial Officer and Chief Operating Officer of Liquidia Corporation.

Liquidia Expands YUTREPIA's Potential Reach with New FDA Designation

Liquidia Corporation, a Delaware corporation headquartered at 419 Davis Drive, Suite 100, Morrisville, North Carolina, disclosed the FDA's action through a press release filed as Exhibit 99.1 to the current report. The company's common stock trades on NASDAQ:LQDA. According to the filing, the Fast Track Designation applies specifically to YUTREPIA (treprostinil) inhalation powder in the context of Raynaud's phenomenon associated with systemic sclerosis, a condition distinct from the pulmonary indications for which YUTREPIA was previously developed.

The filing was made under Item 8.01, "Other Events," indicating that the disclosure did not fall within other enumerated current report categories. Liquidia noted that the press release dated September 3, 2026 is incorporated by reference into that item. The FDA's Fast Track program is a process intended to facilitate the development and expedite the review of drugs that treat serious conditions, according to general regulatory context, though the filing itself does not elaborate further on the designation's procedural implications beyond announcing its grant.

What Was Disclosed

Liquidia Corporation reported that the FDA granted Fast Track Designation to its YUTREPIA (treprostinil) inhalation powder product for treating Raynaud's phenomenon associated with systemic sclerosis. The disclosure was made via a press release filed as Exhibit 99.1, dated September 3, 2026.